Converging Motivs

BioMotiv LLC and Torrey Pines Investment are no strangers to investing in academic discoveries, but nonetheless are teaming up to cover even more ground. The deal gives Torrey Pines access to an existing stable of early stage physician scientist discoveries, while BioMotiv will be able to tap into the VC's network of CROs.

BioMotiv CEO Baiju Shah said the partners plan to co-invest up to $40 million over the next seven years in up to 20 preclinical projects originating from research institutions...